Showing results (401-410 of 775) with videos related to
Sort By:
Pageof 78
Dermatology and Therapy|May 13, 2022
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World SettingBruce Strober, Dhaval Patil, Robert R McLean, et al.The American Journal of Managed Care|November 14, 2022
Perspectives on nonmedical switching and the COVID-19 pandemic: a narrative reviewJoseph F Merola, April W Armstrong, Sharon Phares, et al.Journal of Psoriasis and Psoriatic Arthritis|November 25, 2024
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North AmericaBruce Strober, Yichen Zhong, Adam Sima, et al.Dermatology and Therapy|October 13, 2025
Risk of Nonmelanoma Skin Cancer in Patients with Moderate-to-Severe Atopic Dermatitis: A United States Population-Based StudyMark Lebwohl, Emma Yue, Whitney S Krueger, et al.Photomedicine and Laser Surgery|October 12, 2010
The use of the 308-nm excimer laser for the treatment of psoriasisSuhail M Hadi, Hanadi Al-Quran, Ana Paula de Sá Earp, et al.Journal of the American Academy of Dermatology|April 2, 2008
Psoriasis treatment patterns: results of a cross-sectional survey of dermatologistsVaishali Patel, Elizabeth J Horn, Steve J Lobosco, et al.Expert Opinion on Pharmacotherapy|December 2, 2020
Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and olderJia C Gao, Veronica K Emmerich, Steven Feldman, et al.Expert Opinion on Biological Therapy|December 15, 2020
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO studyAlan Menter, Petr Arenberger, Sigrid Balser, et al.Journal of Drugs in Dermatology : JDD|August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.Journal of Drugs in Dermatology : JDD|August 13, 2015
Reproducible Novel Transcriptional Differences Between Psoriatic Lesional and Non-Lesional Skin Show Increased Inflammation and MetabolismDaniel J Aires, Graham Rockwell, Alan Menter, et al.Pageof 78